732 related articles for article (PubMed ID: 32133005)
1. Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy.
Zemek RM; Chin WL; Nowak AK; Millward MJ; Lake RA; Lesterhuis WJ
Front Immunol; 2020; 11():223. PubMed ID: 32133005
[TBL] [Abstract][Full Text] [Related]
2. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
Front Immunol; 2020; 11():784. PubMed ID: 32457745
[TBL] [Abstract][Full Text] [Related]
3. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
Shi T; Song X; Wang Y; Liu F; Wei J
Front Immunol; 2020; 11():683. PubMed ID: 32411132
[TBL] [Abstract][Full Text] [Related]
4. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
[TBL] [Abstract][Full Text] [Related]
5. Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade.
Liu Y; Cai J; Liu W; Lin Y; Guo L; Liu X; Qin Z; Xu C; Zhang Y; Su X; Deng K; Yan G; Liang J
Cell Death Dis; 2020 Dec; 11(12):1062. PubMed ID: 33311488
[TBL] [Abstract][Full Text] [Related]
6. Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints.
Shi T; Ma Y; Yu L; Jiang J; Shen S; Hou Y; Wang T
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29735917
[TBL] [Abstract][Full Text] [Related]
7. The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment.
Luo H; Wang W; Mai J; Yin R; Cai X; Li Q
Front Immunol; 2023; 14():1267918. PubMed ID: 37881432
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment.
Uche IK; Kousoulas KG; Rider PJF
Viruses; 2021 Jun; 13(7):. PubMed ID: 34206677
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of immunogenic cell death and immune checkpoint blockade therapy.
Lin RA; Lin JK; Lin SY
Kaohsiung J Med Sci; 2021 Jun; 37(6):448-458. PubMed ID: 33636043
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment.
Arrieta VA; Dmello C; McGrail DJ; Brat DJ; Lee-Chang C; Heimberger AB; Chand D; Stupp R; Sonabend AM
J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36647828
[TBL] [Abstract][Full Text] [Related]
11. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
Front Immunol; 2021; 12():669150. PubMed ID: 34267748
[TBL] [Abstract][Full Text] [Related]
12. Immune Aging and Immunotherapy in Cancer.
Kaiser M; Semeraro MD; Herrmann M; Absenger G; Gerger A; Renner W
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209842
[TBL] [Abstract][Full Text] [Related]
13. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment.
Zemek RM; De Jong E; Chin WL; Schuster IS; Fear VS; Casey TH; Forbes C; Dart SJ; Leslie C; Zaitouny A; Small M; Boon L; Forrest ARR; Muiri DO; Degli-Esposti MA; Millward MJ; Nowak AK; Lassmann T; Bosco A; Lake RA; Lesterhuis WJ
Sci Transl Med; 2019 Jul; 11(501):. PubMed ID: 31316010
[TBL] [Abstract][Full Text] [Related]
14. Computational Biology Predicts the Efficacy of Tumor Immune Checkpoint Blockade.
Kang W; Tong Y; Zhang W; Jian M; Zhang A; Ren G; Fan H; Yang J
Biomed Res Int; 2022; 2022():6087751. PubMed ID: 36212709
[TBL] [Abstract][Full Text] [Related]
15. Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade.
Appleton E; Hassan J; Chan Wah Hak C; Sivamanoharan N; Wilkins A; Samson A; Ono M; Harrington KJ; Melcher A; Wennerberg E
Front Immunol; 2021; 12():754436. PubMed ID: 34733287
[TBL] [Abstract][Full Text] [Related]
16. The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
van Dijk N; Funt SA; Blank CU; Powles T; Rosenberg JE; van der Heijden MS
Eur Urol; 2019 Mar; 75(3):435-444. PubMed ID: 30274701
[TBL] [Abstract][Full Text] [Related]
17. Conserved immuno-collagenic subtypes predict response to immune checkpoint blockade.
Mei J; Cai Y; Xu R; Li Q; Chu J; Luo Z; Sun Y; Shi Y; Xu J; Li D; Liang S; Jiang Y; Liu J; Qian Z; Zhou J; Wan M; Yang Y; Zhu Y; Zhang Y; Yin Y
Cancer Commun (Lond); 2024 May; 44(5):554-575. PubMed ID: 38507505
[TBL] [Abstract][Full Text] [Related]
18. Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade.
Choi Y; Seok SH; Yoon HY; Ryu JH; Kwon IC
Adv Drug Deliv Rev; 2024 Jun; 209():115306. PubMed ID: 38626859
[TBL] [Abstract][Full Text] [Related]
19. Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors.
Dammeijer F; Lau SP; van Eijck CHJ; van der Burg SH; Aerts JGJV
Cytokine Growth Factor Rev; 2017 Aug; 36():5-15. PubMed ID: 28693973
[TBL] [Abstract][Full Text] [Related]
20. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]